What is Ultragenyx Pharmaceutical's D&A?

Ultragenyx Pharmaceutical (RARE) reported D&A of $8M in Q1 2026.

How has Ultragenyx Pharmaceutical's D&A changed year-over-year?

Ultragenyx Pharmaceutical's D&A decreased by 11.1% year-over-year, from $9M to $8M.

What is the long-term trend for Ultragenyx Pharmaceutical's D&A?

Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's D&A has grown at a 27.5% compound annual growth rate (CAGR), from $13.24M to $35M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ultragenyx Pharmaceutical RARE D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

AmgenAMGN

$1.12B-19.5%

Ionis PharmaceuticalsIONS

$3.3M+48.2%

Arrowhead ResearchARWR

$6.37M+4.7%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

ModernaMRNA

$59M+51.3%

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's D&A?: Ultragenyx Pharmaceutical (RARE) reported D&A of $8M in Q1 2026.
How has Ultragenyx Pharmaceutical's D&A changed year-over-year?: Ultragenyx Pharmaceutical's D&A decreased by 11.1% year-over-year, from $9M to $8M.
What is the long-term trend for Ultragenyx Pharmaceutical's D&A?: Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's D&A has grown at a 27.5% compound annual growth rate (CAGR), from $13.24M to $35M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.